FIELD: biotechnology; medicine; biochemistry; molecular biology.
SUBSTANCE: what is declared is a pharmaceutical composition containing a conjugate of CEACAM6 with urease, as well as a method for its preparation, use and kit.
EFFECT: invention can be used in medicine for cancer therapy.
31 cl, 15 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| CONJUGATE OF LUMINESCENT SILICON DIOXIDE NANOPARTICLES WITH RECOMBINANT SINGLE-DOMAIN C7B LAMA NANO-MONOANTIBODIES, CAPABLE OF SPECIFICALLY INTERACTING WITH RECOMBINANT HER2/NEU PROTEIN - ANALOGUE OF EPIDERMAL GROWTH FACTOR NATURAL RECEPTOR EGFR/ERBB OF HUMAN CELLS | 2017 |
|
RU2679075C1 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| FLUORESCENT CONJUGATES AND USE THEREOF FOR TUMOR DIAGNOSTICS | 2016 |
|
RU2720976C2 |
| METHOD FOR SELECTION AND PRODUCTION OF SELECTIVE AND MULTISPECIFIC THERAPEUTIC MOLECULES WITH SPECIFIED PROPERTIES, INCLUDING, AT LEAST TWO, DIFFERENT TARGET GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2644263C2 |
| CD37 BINDING MOLECULES AND IMMUNOCONJUGATES | 2011 |
|
RU2610662C9 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| CREATION OF CONJUGATES OF GD2-SPECIFIC ANTIBODIES AND FRAGMENTS OF GD2-SPECIFIC ANTIBODIES WITH PREPARATIONS | 2019 |
|
RU2733430C1 |
| PRODUCING PEGYLATED FRAGMENTS OF GD2-SPECIFIC ANTIBODIES INDUCING DIRECT CELL DEATH OF GD2-POSITIVE TUMOR CELLS, AND USE THEREOF IN THERAPY OF GD2-POSITIVE TUMORS | 2017 |
|
RU2663104C1 |
| CONJUGATES OF ANTIBODIES AND DRUGS CHARACTERIZED IN HIGH IN VIVO TOLERANCE | 2018 |
|
RU2764031C2 |
